Dose dependence of emergence of resistance to linezolid in Enterococcus faecalis in vivo

Journal of Infectious Diseases

Volumn 195, Issue 10, 2007, Pages 1480-1488

  Bourgeois Nicolaos, Nadège ^a,b,c   Massias, Laurent ^d   Couson, Brigitte ^e   Butel, Marie José ^b   Andremont, Antoine ^a,c,d   Doucet Populaire, Florence ^b,e  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d BICHAT HOSPITAL   (France)

^e CENTRE HOSPITALIER DE VERSAILLES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID;

ANIMAL EXPERIMENT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL MUTATION; BACTERIUM MUTANT; CONTROLLED STUDY; DIGESTIVE SYSTEM; DOSE RESPONSE; ENTEROCOCCUS FAECALIS; GNOTOBIOTICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA SEQUENCE;

ACETAMIDES; ANIMALS; ANTI-INFECTIVE AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; DNA PRIMERS; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS FAECALIS; GRAM-POSITIVE BACTERIAL INFECTIONS; MICE; OXAZOLIDINONES; RNA, BACTERIAL; RNA, RIBOSOMAL; RNA, RIBOSOMAL, 16S; RNA, RIBOSOMAL, 5S;

EID: 34248215686     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/513876     Document Type: Article

References (49)

1. Andremont A, Brun-Buisson C, Struelens M. Evaluating and predicting the ecologic impact of antibiotics. Clin Microbiol Infect 2001; 7(Suppl 5):1-6.
2. Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 2001; 1: 101-14.
3. Scanvic-Hameg A, Chachaty E, Rey J, et al. Impact of quinupristin/ dalfopristin (RP59500) on the faecal microflora in healthy volunteers. J Antimicrob Chemother 2002; 49:135-9.
4. Cremieux AC, Muller-Serieys C, Panhard X, et al. Emergence of resistance in normal human aerobic commensal flora during telithromycin and amoxicillin-clavulanic acid treatments. Antimicrob Agents Chemother 2003; 47:2030-5.
5. Andremont A, Trancrede C, Desnottes JF. Effect of oral spiramycin on the faecal and oral bacteria in human volunteers. J Antimicrob Chemother 1991; 27:355-60.
6. Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious gram-positive infections. Drugs 2001; 61:525-51.
7. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003; 138:135-42.
8. Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998; 42:3251-5.
9. Fines M, Leclercq R. Activity of linezolid against Gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors. J Antimicrob Chemother 2000; 45:797-802.
10. Prystowsky J, Siddiqui F, Chosay J, et al. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother 2001; 45:2154-6.
11. Jones RN, Ross JE, Fritsche TR, Sader HS. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J Antimicrob Chemother 2006; 57:279-87.
12. Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358:207-8.
13. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001; 357:1179.
14. Swoboda S, Fritz S, Martignoni ME, et al. Varying linezolid susceptibility of vancomycin-resistant Enterococcus faecium isolates during therapy: a case report. J Antimicrob Chemother 2005; 56:787-9.
15. Boo TW, Hone R, Sheehan G, Walsh M. Isolation of linezolid-resistant Enterococcus faecalis. J Hosp Infect 2003; 53:312-3.
16. Bersos Z, Maniati M, Kontos F, Petinaki E, Maniatis AN. First report of a linezolid-resistant vancomycin-resistant Enterococcus faecium strain in Greece. J Antimicrob Chemother 2004; 53:685-6.
17. Jones RN, Della-Latta P, Lee LV, Biedenbach DJ. Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2002; 42:137-9.
18. Rahim S, Pillai SK, Gold HS, Venkataraman L, Inglima K, Press RA. Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid. Clin Infect Dis 2003; 36:E146-8.
19. Meka VG, Gold HS. Antimicrobial resistance to linezolid. Clin Infect Dis 2004; 39:1010-5.
20. Auckland C, Teare L, Cooke F, et al. Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. J Antimicrob Chemother 2002; 50:743-6.
21. Paulsen IT, Banerjei L, Myers GS, et al. Role of mobile DNA in the evolution of vancomycin-resistant Enterococcus faecalis. Science 2003; 299:2071-4.
22. Marshall SH, Donskey CJ, Hutton-Thomas R, Salata RA, Rice LB. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob Agents Chemother 2002; 46:3334-6.
23. Wilson P, Andrews JA, Charlesworth R, et al. Linezolid resistance in clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 2003; 51:186-8.
24. Ruggero KA, Schroeder LK, Schreckenberger PC, Mankin AS, Quinn JP. Nosocomial superinfections due to linezolid-resistant Enterococcus faecalis: evidence for a gene dosage effect on linezolid MICs. Diagn Microbiol Infect Dis 2003; 47:511-3.
25. Pecquet S, Chachaty E, Tancrede C, Andremont A. Effects of roxithromycin on fecal bacteria in human volunteers and resistance to colonization in gnotobiotic mice. Antimicrob Agents Chemother 1991; 35:548-52.
26. Pecquet S, Andremont A, Tancrede C. Selective antimicrobial modulation of the intestinal tract by norfloxacin in human volunteers and in gnotobiotic mice associated with a human fecal flora. Antimicrob Agents Chemother 1986; 29:1047-52.
27. Doucet-Populaire F, Trieu-Cuot P, Andremont A, Courvalin P. Conjugal transfer of plasmid DNA from Enterococcus faecalis to Escherichia coli in digestive tracts of gnotobiotic mice. Antimicrob Agents Chemother 1992; 36:502-4.
28. Doucet-Populaire F, Trieu-Cuot P, Dosbaa I, Andremont A, Courvalin P. Inducible transfer of conjugative transposon Tn1545 from Enterococcus faecalis to Listeria monocytogenes in the digestive tracts of gnotobiotic mice. Antimicrob Agents Chemother 1991; 35:185-7.
29. Moubareck C, Bourgeois N, Courvalin P, Doucet-Populaire F. Multiple antibiotic resistance gene transfer from animal to human enterococci in the digestive tract of gnotobiotic mice. Antimicrob Agents Chemother 2003; 47:2993-6.
30. Bourgeois-Nicolaos N, Moubareck C, Mangeney N, Butel MJ, Doucet-Populaire F. Comparative study of vanA gene transfer from Enterococcus faecium to Enterococcus faecalis and to Enterococcus faecium in the intestine of mice. FEMS Microbiol Lett 2006; 254:27-33.
31. Perrin-Guyomard A, Poul JM, Corpet DE, Sanders P, Fernandez AH, Bartholomew M. Impact of residual and therapeutic doses of ciprofloxacin in the human-flora-associated mice model. Regul Toxicol Pharmacol 2005; 42:151-60.
32. Kuhn I, Iversen A, Burman LG, et al. Comparison of enterococcal populations in animals, humans, and the environment - a European study. Int J Food Microbiol 2003; 88:133-45.
33. 14C] linezolid to healthy human subjects. Drug Metab Dispos 2001; 29:1136-45.
34. Lode H, Von der Hoh N, Ziege S, Borner K, Nord CE. Ecological effects of linezolid versus amoxicillin/clavulanic acid on the normal intestinal microflora. Scand J Infect Dis 2001; 33:899-903.
35. Jacob AE, Hobbs S. Conjugal transfer of plasmid-borne multiple antibiotic resistance in Streptococcus faecalis var. zymogenes. J Bacteriol 1974; 117:360-72.
36. Clinical Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard [M7-A7]. 7th ed. Wayne, PA: CLSI, 2006.
37. Clinical Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: approved standard [M100-S16]. 16th Informational Supplement. Wayne, PA: CLSI, 2006.
38. Rea MC, Cogan TM. Glucose prevents citrate metabolism by enterococci. Int J Food Microbiol 2003; 88:201-6.
39. Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996; 40:839-45.
40. Bonora MG, Ligozzi M, Luzzani A, Solbiati M, Stepan E, Fontana R. Emergence of linezolid resistance in Enterococcus faecium not dependent on linezolid treatment. Eur J Clin Microbiol Infect Dis 2006; 25: 197-8.
41. Oprea SF, Zaidi N, Donabedian SM, Balasubramaniam M, Hershberger E, Zervos MJ. Molecular and clinical epidemiology of vancomycin-resistant Enterococcus faecalis. J Antimicrob Chemother 2004; 53:626-30.
42. Bassetti M, Farrel PA, Callan DA, Topal JE, Dembry LM. Emergence of linezolid-resistant Enterococcus faecium during treatment of enterococcal infections. Int J Antimicrob Agents 2003; 21:593-4.
43. Duval-Iflah Y, Raibaud P, Tancrède C, Rousseau M. R plasmid transfer from Serratia liquifaciens to Escherichia coli in vitro and in vivo in the digestive tract of gnotobiotic mice associated with human fecal flora. Infect Immun 1980; 28:981-90.
44. Rodriguez JC, Cebrian L, Lopez M, Ruiz M, Royo G. Mutant prevention concentration: a new tool for choosing treatment in nontuberculous mycobacterial infections. Int J Antimicrob Agents 2004; 24:352-6.
45. Croisier D, Etienne M, Piroth L, et al. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants. J Antimicrob Chemother 2004; 54:640-7.
46. Etienne M, Croisier D, Charles PE, et al. Effect of low-level resistance on subsequent enrichment of fluoroquinolone-resistant Streptococcus pneumoniae in rabbits. J Infect Dis 2004; 190:1472-5.
47. Zinner SH, Lubenko IY, Gilbert D, et al. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. J Antimicrob Chemother 2003; 52:616-22.
48. Lobritz M, Hutton-Thomas R, Marshall S, Rice LB. Recombination proficiency influences frequency and locus of mutational resistance to linezolid in Enterococcus faecalis. Antimicrob Agents Chemother 2003; 47:3318-20.
49. Donskey CJ. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin Infect Dis 2004; 39: 219-26.